FDA's guidance on investigating out-of-specification (OOS) test results calls for failure investigations, and notes that much of it can also help when examining out-of-trend (OOT) results. This 90-minute webinar explains FDA requirements and guidelines for handling out-of-trend results in the pharmaceutical laboratory.
You'll review the relevant FDA regulations and the final Guidance for Industry on investigating OOS results, how OOS and OOT results differ, and how to write SOPs for OOT situations and laboratory failures. The session covers what to investigate and how, retesting, and evaluating results with historical data, QC samples and product control charts.
It also explains how to find the root cause, develop CAPA plans, prevent OOS results before they happen, and document OOS, OOT, investigations, root causes and CAPA in an FDA-compliant way.
WHY SHOULD YOU ATTEND?
Most companies have procedures for OOS results but not for OOT situations, and many are unsure how to interpret and apply FDA's guidance to them. Managing OOT results well also helps you avoid time-consuming OOS investigations later.
This session suits lab supervisors and managers, QA managers and staff, pharmaceutical R&D and documentation personnel, consultants, contract laboratories and CROs.
AREA COVERED
- FDA regulations and guidelines
- FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production
- The difference between OOS and OOT results
- Developing SOPs for OOT situations and laboratory failures
- Investigating OOT results: what and how
- Retesting OOT results
- Using historical data for OOT evaluation
- Using QC samples and product control charts
- Developing corrective and preventive action plans
- Finding the root cause of OOT results
- Strategies to prevent OOS situations before they occur
- FDA-compliant documentation of OOS, OOT, failure investigations, root causes and CAPA
LEARNING OBJECTIVES
- Explain FDA requirements and guidance that apply to OOT results
- Distinguish OOS from OOT results
- Write SOPs for OOT situations and laboratory failures
- Investigate and retest OOT results using historical data and control charts
- Find root causes and develop CAPA plans
- Document OOS, OOT, investigations and CAPA to FDA expectations
WHO WILL BENEFIT?
- Lab Supervisors and Managers
- QA managers and personnel
- Pharmaceutical R&D personnel
- Documentation
- Consultants
- Contract laboratories
- CROs
Most companies have procedures for OOS results but not for OOT situations, and many are unsure how to interpret and apply FDA's guidance to them. Managing OOT results well also helps you avoid time-consuming OOS investigations later.
This session suits lab supervisors and managers, QA managers and staff, pharmaceutical R&D and documentation personnel, consultants, contract laboratories and CROs.
- FDA regulations and guidelines
- FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production
- The difference between OOS and OOT results
- Developing SOPs for OOT situations and laboratory failures
- Investigating OOT results: what and how
- Retesting OOT results
- Using historical data for OOT evaluation
- Using QC samples and product control charts
- Developing corrective and preventive action plans
- Finding the root cause of OOT results
- Strategies to prevent OOS situations before they occur
- FDA-compliant documentation of OOS, OOT, failure investigations, root causes and CAPA
- Explain FDA requirements and guidance that apply to OOT results
- Distinguish OOS from OOT results
- Write SOPs for OOT situations and laboratory failures
- Investigate and retest OOT results using historical data and control charts
- Find root causes and develop CAPA plans
- Document OOS, OOT, investigations and CAPA to FDA expectations
- Lab Supervisors and Managers
- QA managers and personnel
- Pharmaceutical R&D personnel
- Documentation
- Consultants
- Contract laboratories
- CROs
Speaker Profile
Kelly Thomas
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
Upcoming Webinars
Medical Device Cybersecurity Following FDA’s 2026 Premarket…
Managing Toxic Employees: Strategies For Leaders To Effecti…
California Meal and Rest Breaks: What You Don't Know Can Co…
Human Error Reduction Techniques for Floor Supervisors
Unlock Employee Loyalty: Stay Interviews Will Keep Them Eng…
Performance of Root Cause Analysis, CAPA, and Effectiveness…
Your AI Advantage: How HR Professionals Can Use Claude to S…
The Anti-Kickback Statute: Enforcement and Recent Updates
Empowering Conflict Resolution: Letting Go to Gain Control
Wage & Hour Laws: Ensuring Compliance with the Fair Labor S…
Using Copilot to Format Legal Documents in Microsoft Word
Dealing With Difficult People: At Work & In Life
Using Stay Interviews To Improve Employee Retention & Engag…
AI in Word - Smarter Writing and Document Creation with Cha…
FDA Current Trends in Compliance and Enforcement for FDA-Re…
Zero Acceptance Sampling to Reduce Inspection Costs
Why EBITDA Doesn't Spell Cash Flow and What Does?
Mastering Tough Conversations: Turn Conflict into Clarity, …
Enhancing Pivot Tables with Images: Visualize Your Data Lik…
Discover how Emotional Intelligence turns AI from a technic…
Understanding Financial Statements for Non-Financial Profes…
SOPs - How to Write Them to Satisfy those Inspectors
Managing Projects When AI Joins the Team: Human Judgment, A…